Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

NCT05429372 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in one combined study: C3391003

Conditions

Interventions

Sponsor

Pfizer